// App-Quantinova.ai

4881 : Empagliflozin reduces mortality in analyses adjusted for control of blood pressure, low density lipoprotein cholesterol and HbA1c over time

Researchers

Presenter

  • B. Zinman

Principal Investigators

  • C. Mathieu

  • S. Kaspers

  • M. Mattheus

  • H.J. Woerle

  • D. Fitchett

Medical Centers

  • Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, and Division of Endocrinology, University of Toronto, Toronto, Canada

  • Department of clinical and experimental medicine, University Hospitals LEuven, Leuven, Belgium

  • Boehringer Ingelheim Pharma GmbH, Ingelheim, Germany

  • St. Michael's Hospital, Division of Cardiology, University of Toronto, Toronto, Canada

Locations

  • Canada

  • Belgium

  • Germany

Companies

  • Boehringer Ingelheim

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Hemoglobin A1c

Drug/Treatment

  • BI-10773

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved